Loading...
Loading...
Dr. Reddy's Laboratories
RDY
announced today that the U.S. Food and Drug Administration (FDA) has
approved ZEMBRACE™SymTouch™ (sumatriptan succinate) injection, a
drug-device combination product intended for the treatment of acute
migraine episodes, with or without aura, in adults who are inadequately
managed with existing treatment regimens. ZEMBRACESymTouch is available
as a prefilled, ready-to-use, single-dose disposable autoinjector
containing 3 mg of sumatriptan, a selective 5-HT1B/ID receptor agonist.
The injection is intended to be given subcutaneously.1
"We are pleased to have received FDA approval for ZEMBRACESymTouch,"
said Raghav Chari, Executive Vice President, Proprietary Products Group
at Dr. Reddy's Laboratories. "ZEMBRACESymTouch is the first branded
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in